One of the most widely fancied small-cap growth shares among professional investors is ultrasound disinfectant business Nanosonics Ltd (ASX: NAN).
It's easy to see why when you consider the impressive financials it handed in for the six months ending December 31 2018. Net profit after tax lifted 221% to $7.1 million, while sales grew 36% to $40.7 million.
In further good news today, Nanosonics revealed that the French health regulator has introduced tougher guidelines for the disinfection of ultrasound devices that could prove a sales juicer for the business.
Melbourne-based professional fund manager Yarra Capital Management is also bullish and has an "overweight" position in Nanosonics in its fund.
In its end of February 2018 review of the position Yarra opined: "We continue to believe NAN offers an attractive growth profile, with the sale of consumables for its devices generating a high-quality, annuity-style revenue stream. Lastly, NAN has a strong balance sheet – it is in a net cash position – to fund future growth and support further product innovation."
As such Nanosonics could be a business for the research list of small-cap growth enthusiasts.
Others soaring in the junior healthcare or pure tech space on the back of positive updates recently include Pro Medicus Ltd (ASX: PME) and Bigtincan Holdings Ltd (ASX: BTH).
